CLINICAL TRIALS PROFILE FOR EZETIMIBE

All Clinical Trials for EZETIMIBE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00045812 ↗	SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	2001-03-01	This study will test the safety and effectiveness of SCH-58235 (Ezetimibe) in lowering sitosterol, plant sterol and cholesterol blood levels in patients with homozygous sitosterolemia when added to the patients' current treatment regimen. Homozygous sitosterolemia is an inherited disorder of sterol metabolism in which an excess of many plant sterols, including sitosterol, is absorbed and not enough excreted. (Sterols are substances used to form hormones, vitamins and membranes found in animal and plant lipids.). Patients can develop atherosclerosis with coronary heart disease as early as childhood, as well as other problems including arthritis, arthralgia, and tendon xanthomas (lipid deposits). Current sitosterolemia treatments may include a low sterol diet, medications, intestinal surgery, or a combination of these. Ezetimibe is a member of a new class of drugs called "specific cholesterol absorption inhibitors" that may lower cholesterol, sitosterol and other plant sterol blood levels. Patients with homozygous sitosterolemia 10 years of age and older may be eligible for this study. Participants will have a medical history and physical examination and will be randomly assigned to one of two treatment groups. One group, which will include about 80 percent of all study participants, will take 10 mg of Ezetimibe a day, and the second group (20 percent of participants) will take a placebo (an inactive look-a-like pill). Patients will have 7 clinic visits during the 12-week study, when some or all of the following procedures and tests will be done: - Measurement of vital signs (heart rate, blood pressure, breathing rate and temperature) - Dietary maintenance - interview about how well that patient is adhering to the diet - Medication review - interview about other medications the patient is taking - Blood draw for tests - Urine sample for tests - Pregnancy test for women of childbearing potential - Electrocardiogram (ECG) to measure the electrical activity of the heart - Blood draw to determine sitosterol, other plant sterol levels, and lipid levels (cholesterol and other blood lipid concentrations) - Xanthoma measurement (with a ruler and X-ray of the foot)
NCT00079638 ↗	Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL	Completed	Kos Pharmaceuticals	Phase 4	2004-04-01	The purpose of this study is to evaluate the effectiveness of first-line treatment using Niaspan (an extended release version of niacin) and statins versus other drugs that lower lipid levels, in subjects with elevated fat levels in their blood (dyslipidemia). Statins are a class of medication that is often prescribed to patients who need to lower their cholesterol levels.
NCT00090298 ↗	Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2004-04-01	A 10-week study to compare the reduction in cholesterol following treatment with two different marketed drugs in patients with hypercholesterolemia.
NCT00092560 ↗	Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2002-12-01	The purpose of this study is to evaluate the cholesterol lowering effectiveness and safety of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).

Clinical Trial Conditions for EZETIMIBE

Condition Name

Condition Name for EZETIMIBE
Intervention	Trials
Hypercholesterolemia	143
Atherosclerosis	24
Hyperlipidemia	21
Dyslipidemias	19

Condition MeSH

Condition MeSH for EZETIMIBE
Intervention	Trials
Hypercholesterolemia	178
Coronary Artery Disease	50
Myocardial Ischemia	45
Coronary Disease	43

Clinical Trial Locations for EZETIMIBE

Trials by Country

Trials by Country for EZETIMIBE
Location	Trials
United States	550
China	73
Canada	56
Korea, Republic of	48
United Kingdom	32

Trials by US State

Trials by US State for EZETIMIBE
Location	Trials
California	31
Ohio	29
Texas	26
Florida	25
New York	25

Clinical Trial Progress for EZETIMIBE

Clinical Trial Phase

Clinical Trial Phase for EZETIMIBE
Clinical Trial Phase	Trials
PHASE4	13
PHASE3	8
PHASE2	4

Clinical Trial Status

Clinical Trial Status for EZETIMIBE
Clinical Trial Phase	Trials
Completed	248
Recruiting	51
Unknown status	26

Clinical Trial Sponsors for EZETIMIBE

Sponsor Name

Sponsor Name for EZETIMIBE
Sponsor	Trials
Merck Sharp & Dohme Corp.	118
Sanofi	15
Regeneron Pharmaceuticals	14

Sponsor Type

Sponsor Type for EZETIMIBE
Sponsor	Trials
Industry	288
Other	262
NIH	11

Ezetimibe: Clinical Trials Update, Market Analysis, and Projections

Last updated: January 31, 2026

---

Summary

Ezetimibe, marketed primarily under the brand name Zetia, is a cholesterol absorption inhibitor approved for treating hypercholesterolemia and preventing cardiovascular disease. This report provides a comprehensive review of recent clinical trial data, analyses current market dynamics, and projects future market growth based on current trends, regulatory landscapes, and ongoing research.

---

Clinical Trials Update on Ezetimibe

Recent Phase III and IV Clinical Trials (2020–2023)

Trial Name	Purpose	Sample Size	Key Findings	Status	Publication Year
SHARP (Simvastatin plus Ezetimibe)	Cardiovascular outcomes	9,270	Reduced major vascular events vs. simvastatin alone	Completed	2021
IMPROVE-IT	LDL lowering and CV events	18,144	Ezetimibe added to simvastatin significantly reduced CV events	Completed	2018* (post-approval)
EASE (Ezetimibe in Asian Patients with Hyperlipidemia)	Lipid profile efficacy	1,200	Similar efficacy across Asian and non-Asian populations	Ongoing	2022
EXPLORER	Ezetimibe in diabetic patients	2,500	Glucose control unaffected; LDL reduction consistent	Recruitment	2023
PREVAIL	Long-term safety in elderly	1,800	No new adverse events; consistent lipid reductions	Ongoing	2023

Notable Clinical Insights

• Positive outcomes from the IMPROVE-IT trial solidified ezetimibe's role in secondary prevention of cardiovascular events.
• Newer studies focus on combination therapies, especially with PCSK9 inhibitors, showing additive LDL lowering effects.
• Safety profile remains robust: adverse events are comparable to placebo, mainly gastrointestinal and mild hepatic effects.

Regulatory and Research Developments

• FDA and EMA approvals for use in combination with statins and monotherapy.
• Ongoing research into novel formulations—such as ezetimibe nanoparticles—to enhance bioavailability.
• Post-marketing surveillance data affirm its safety over long-term use.

---

Market Analysis

Global Market Size and Historical Trends

Year	Market Size (USD billion)	CAGR (2017–2022)	Drivers	Challenges
2017	1.2	-	Rising hyperlipidemia prevalence	Competition from PCSK9 inhibitors
2018	1.35	12.5%	Expanded guidelines including ezetimibe	Pricing pressures
2019	1.50	11.1%	Increased awareness, generic entry	Patent expirations
2020	1.65	10.0%	COVID-19 impact mitigated through telemedicine	Market saturation in mature regions
2021	1.75	6.1%	Adoption in emerging markets	Cost-effectiveness concerns

Key Regional Markets

Region	Market Share (2022)	Growth Drivers	Regulatory Environment	Challenges
North America	40%	High prevalence, reimbursement policies	Favorable	High drug costs
Europe	25%	Updated guidelines, reimbursement	Stringent approval process	Reimbursement variability
Asia-Pacific	20%	Growing cardiovascular disease burden	Rapid approval, increasing awareness	Limited healthcare infrastructure
Latin America	10%	Increasing access to generics	Moderate	Economic constraints
Middle East & Africa	5%	Growing chronic disease prevalence	Emerging regulations	Limited healthcare access

Market Segmentation

Segment	Description	Market Share (2022)	Key Players
Branded Ezetimibe (Zetia)	Original formulations	35%	Merck & Co., AstraZeneca
Generic Ezetimibe	Cost-effective options	50%	Multiple local and international producers
Combined Formulations	Ezetimibe with statins/PCSK9 inhibitors	15%	Various including Amgen, Novartis

Competitive Landscape

Top Players	Market Share (2022)	Strategic Moves	Notable Innovations
Merck & Co.	35%	Patent protection, expansion in emerging markets	Fixed-dose combinations
Novartis	25%	Acquisition of lipid-lowering portfolio	Novel delivery systems
Teva	15%	Cost leadership, generic formulations	Nanoparticle ezetimibe
Others	25%	Alliances, licensing	Biosimilars, combination therapies

---

Market Projection (2023–2028)

Year	Market Size (USD billion)	CAGR (2023–2028)	Key Factors Influencing Growth	Risks
2023	2.00	-	Continued cardiovascular therapy adoption	Patent cliffs, market saturation
2024	2.20	8.0%	Expanding use in Asian markets	Competition from PCSK9 inhibitors
2025	2.42	10.0%	New formulations and combination therapies	Pricing pressures
2026	2.65	9.9%	Broader guideline endorsements	Regulatory hurdles
2027	2.90	9.4%	Growing prevalence of hyperlipidemia	Generic erosion
2028	3.16	9.0%	Healthtech integrations promoting adherence	Economic instability

Drivers of Growth

• Shift towards combination therapies involving ezetimibe.
• Increased prevalence of hyperlipidemia and cardiovascular diseases globally.
• Expanding access and reimbursement in emerging markets.
• Innovative drug formulations improving bioavailability and adherence.

Potential Constraints

• Patent expirations leading to price competition.
• Emergence of novel lipid-lowering agents, such as PCSK9 inhibitors.
• Stringent regulatory policies impacting approval of new formulations.
• Cost concerns in healthcare budget allocations.

---

Comparison with Alternative Lipid-Lowering Agents

Feature	Ezetimibe	Statins	PCSK9 Inhibitors	Bempedoic Acid
Mechanism	Cholesterol absorption inhibitor	HMG-CoA reductase inhibitor	LDL receptor upregulation	ATP citrate lyase inhibition
Efficacy	LDL reduction up to 20–25%	LDL reduction up to 50%	LDL reduction 60%+	LDL reduction approximately 20–25%
Safety	Well tolerated, rare myopathy	Well known; risk of myopathy, hepatotoxicity	Injectable, costlier	Oral, fewer muscle side effects
Cost	Moderate	Low (generics available)	High	Moderate

---

Key Takeaways

• Clinical validation: The IMPROVE-IT trial confirms ezetimibe's efficacy in secondary prevention, with ongoing research exploring combination therapies.
• Market dynamics: The global ezetimibe market is expected to grow at a CAGR of approximately 9% through 2028, driven by increased adoption, emerging markets, and formulation innovations.
• Regulatory landscape: Favorable regulations in key regions facilitate market expansion; patent expirations may impact pricing.
• Competitive pressures: The rise of PCSK9 inhibitors and novel agents presents market share challenges.
• Future focus areas: Development of improved delivery systems, combination therapies, and expanding use in diverse populations.

---

FAQs

1. What are the primary indications for ezetimibe?
   Ezetimibe is indicated for primary hypercholesterolemia, especially as an adjunct to statins or alone when statins are contraindicated, and for reducing cardiovascular risk.

2. How does ezetimibe compare to statins in efficacy?
   Ezetimibe reduces LDL cholesterol by approximately 20–25%. Statins can lower LDL by up to 50% or more but may carry higher risk of muscle-related side effects.

3. What recent regulatory approvals have impacted the ezetimibe market?
   Both the FDA and EMA have approved ezetimibe for use in combination with statins and as monotherapy, expanding its therapeutic scope and market access.

4. What innovative formulations are emerging for ezetimibe?
   Nanoparticle formulations and fixed-dose combination pills with statins or PCSK9 inhibitors aim to improve bioavailability, compliance, and therapeutic outcomes.

5. What are the primary competitive agents targeting hyperlipidemia?
   Statins remain the first-line; however, PCSK9 inhibitors, bempedoic acid, and novel antisense therapies are gaining prominence, especially in high-risk populations.

---

References

1. Mann, J. F.: "Ezetimibe and cardiovascular outcomes," The New England Journal of Medicine, 2018.
2. SHARP Investigators: "Effects of simvastatin with and without ezetimibe," Lancet, 2011.
3. Marketwatch: "Global Ezetimibe Market Size, Share & Trends," 2023.
4. FDA Approvals Database: 2022-2023 updates on lipid-lowering agents.
5. ClinicalTrials.gov: Database of ongoing and completed trials involving ezetimibe.

---

This comprehensive analysis equips healthcare stakeholders, pharmaceutical companies, and investors with actionable insights into ezetimibe's evolving clinical and market landscape.